PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 27 PubMed articles · model: gemma4:31b
Summary
Soy-derived phospholipids, including phosphatidylinositol, are utilized as therapeutic agents for cardiovascular health and as delivery systems for various pharmacological compounds [PMID:18311664, PMID:33304099].
Background
Soy phospholipids are plant-based lipids used in the food and pharmaceutical industries, often formulated as liposomes or complexes to improve the delivery and bioavailability of other substances [PMID:36338387, PMID:10534761].
Active compounds
Key components include soy phosphatidylinositol (PI) and phospholipids containing linoleic acid (LA) acyl chains [PMID:18311664, PMID:18189424].
Mechanism of action
Soy phosphatidylinositol (PI) stimulates the production of HDL by the liver through MAPK stimulation and a peroxisome proliferator-activated receptor alpha (PPAR-α) dependent process, specifically influenced by linoleic acid content [PMID:18311664, PMID:18189424].
Clinical evidence
Evidence BCardiovascular Health (HDL and Triglycerides)
Soy phosphatidylinositol (PI) was shown to raise plasma HDL-cholesterol and apolipoprotein A-I levels and reduce triglyceride levels in humans [PMID:18311664].
Evidence BMetabolic Syndrome (Endotoxemia and Gut Barrier)
A comparator beverage formulated with soy phospholipid and palm/coconut oil was used as a control; no adverse effects were reported in participants with metabolic syndrome [PMID:37513677].
Safety & adverse effects
Soy phospholipids have been shown to be safe in clinical trials at doses exceeding 5 g [PMID:18311664]. An intravenous emulsion containing 92.5% soy phospholipid was completed by healthy volunteers without significant toxicities, although a slight dose-dependent increase in indirect bilirubin was observed at 24 hours [PMID:12841798].
Evidence summary
Evidence is primarily based on phase I/II clinical trials and in vitro studies, demonstrating safety and efficacy in modulating lipid profiles and serving as a biocompatible drug delivery vehicle.
PubMed sources
- 1.PMID: 18311664 (2008) — Phospholipids as cardiovascular therapeutics. · Current opinion in investigational drugs (London, England : 2000)
- 2.PMID: 36338387 (2021) — Characterization of milk and soy phospholipid liposomes and inflammation in 3T3-L1 adipocytes. · JDS communications
- 3.PMID: 12841798 (2003) — Safety and pharmacokinetics of an endotoxin-binding phospholipid emulsion. · The Annals of pharmacotherapy
- 4.PMID: 37815121 (2023) — Improving the Physicochemical Stability of Soy Phospholipid-Stabilized Emulsions Loaded with Lutein by the Addition of Sphingomyelin and Cholesterol: Inspired by a Milk Fat Globule Membrane. · Journal of agricultural and food chemistry
- 5.PMID: 33304099 (2020) — ArtinM Grafted Phospholipid Nanoparticles for Enhancing Antibiotic Cellular Uptake Against Intracellular Infection.